Arca Biopharma (ABIO)
Arca Biopharma Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ABIO Revenues Range, Past 5 Years
| Minimum | 0.063M | Sep 2007 |
| Maximum | 45.82M | Jun 2007 |
| Average | 15.32M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ABIO related companies
ABIO News
RT@GarethSoloway Good accumulation on $ABIO today ahead of ASCO.Should continue to climb the next two weeks. Bonus would be news if it hit.
about 3 days ago by InTheMoneyStocks
about 3 days ago by InTheMoneyStocks
Good accumulation on $ABIO today ahead of ASCO. Should continue to climb over the next two weeks. Bonus would be news if it hit.
about 3 days ago by GarethSoloway
about 3 days ago by GarethSoloway
Bio amazing. $ROSG truly a run for the ages. Just holding my small bios $ABIO and $ANX. Be interesting to see if ASCO conference pops them.
about 3 days ago by GarethSoloway
about 3 days ago by GarethSoloway
$ABIO inverted hammer candle formed on daily chart - about time for a reversal me thinks.
about 45 days ago by Good2go
about 45 days ago by Good2go
$ABIO filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FEY
about 51 days ago by MarketBrief
about 51 days ago by MarketBrief
Love the jumps/pumps in $ABIO ... it did a 26% jump just the other day ... don't know why, but stock seems way undervalued at below $1
about 59 days ago by scherf_com
about 59 days ago by scherf_com
$ABIO ready to go nice patern on the daily charts + bio's are hot :)
about 90 days ago by kristofdeblock
about 90 days ago by kristofdeblock
$DARA nice micro bio run today. $ABIO still my favorite that has not run yet. Holding some.
about 110 days ago by GarethSoloway
about 110 days ago by GarethSoloway
Watch $ABIO. Sympathy off other bio runners. Starting to rock N roll
about 111 days ago by GarethSoloway
about 111 days ago by GarethSoloway
ARCA biopharma (ABIO) Awarded U.S. Patent for Methods of Treatment with Bucindolol
Dec 30, 8:03AM Street Insider
Dec 30, 8:03AM Street Insider
ARCA biopharma (ABIO) Enters 1.75M Unit Private Placement; Sees $1.5M in New Proceeds
Dec 22, 8:09AM Street Insider
Dec 22, 8:09AM Street Insider
ARCA biopharma Announces Private Placement of $1.75 Million with Institutional Investors
Dec 22, 8:00AM Business Wire
Dec 22, 8:00AM Business Wire
Arca Biopharma (ABIO) shares now up 94% following resumption after second circuit breaker
Nov 16, 12:38PM Street Insider
Nov 16, 12:38PM Street Insider
ARCA biopharma (ABIO) Reports Substanital Improvement in Onset of Atrial Fibrillation Using Gencaro
Nov 16, 11:50AM Street Insider
Nov 16, 11:50AM Street Insider
ARCA Biopharma halted for circuit breaker after spiking on trial results
Nov 16, 11:49AM FlyOnTheWall
Nov 16, 11:49AM FlyOnTheWall
ARCA biopharma Announces Planned Expansion of Gencaro Development to Atrial Fibrillation
May 26, 8:25AM Business Wire
May 26, 8:25AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABIO | 0.69 | +0.14 | +25.45% | 7.259M |
| ABH | 11.83 | +0.00 | +0.00% | 1.149B |
| ABFS | 12.99 | +0.15 | +1.17% | 330.60M |
| ABD | 9.40 | -0.08 | -0.84% | 523.11M |
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ACH | 10.07 | -0.25 | -2.42% | 1.589B |
| ACGL | 38.31 | -0.31 | -0.80% | 5.188B |
| ACG | 8.20 | +0.00 | +0.00% | |
| ACFN | 8.89 | -0.26 | -2.84% | 157.80M |
| ACFCD | 2.18 | +0.33 | +17.84% |
